Morphing immune cells to treat diseases by utilizing a cell type-selective, conditionally activated delivery platform
MorphImmune is pioneering the use of chemistry to precisely modulate dysfunctional or malignant cells to treat disease
MorphImmune’s Novel Approach:
Targeted Immune Modulators
MorphImmune uses a platform technology of small-molecule, rapidly penetrating, cost-effective drug-targeting of errant immune cells. We deliver drugs that can reprogram pro-inflammatory and pro-tumor immune cells to an anti-inflammatory and anti-tumor milieu. Using immune cell specific ligands coupled with pathway re-programmers, the technology tackles core chronic and acute disease pathways. This approach differentiates MorphImmune from other immune-biopharmaceuticals that block downstream changes once the immune cells have been hijacked. MorphImmune addresses immune changes at its core alterations.